IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Jou
Go back to IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Jou| (NASDAQ: IDYA) | Delayed: 34.71 -1.41 (3.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.12 | 52 Week High | $ | |||
| Open | $36.35 | 52 Week Low | $ | |||
| Day High | $36.35 | P/E | N/A | |||
| Day Low | $34.54 | EPS | $ | |||
| Volume | 1,128,966 | |||||



